<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04881747</url>
  </required_header>
  <id_info>
    <org_study_id>17016</org_study_id>
    <secondary_id>H8H-MC-LAIA</secondary_id>
    <nct_id>NCT04881747</nct_id>
  </id_info>
  <brief_title>A Study to Compare Two Different Formulations of Lasmiditan in Healthy Participants</brief_title>
  <official_title>Bioequivalence of Lasmiditan Oral Disintegrating Tablet Compared to Current Immediate-Release Tablet Formulation to Support Treatment of Migraine</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eli Lilly and Company</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Eli Lilly and Company</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main purpose of this study is to compare the amount of lasmiditan that gets into the&#xD;
      blood stream and how long it takes the body to get rid of it, when given as a&#xD;
      oral-disintegrating (OD) tablet compared to immediate-release (IR) tablet formulation. The&#xD;
      information about any adverse effects experienced will be collected and the tolerability of&#xD;
      lasmiditan when administered as OD tablet will also be evaluated.&#xD;
&#xD;
      Screening is required within 28 days prior to the start of the study. For each participant,&#xD;
      the total duration of the clinical trial will be about 5 weeks, including screening.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">May 14, 2021</start_date>
  <completion_date type="Actual">July 24, 2021</completion_date>
  <primary_completion_date type="Actual">July 24, 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pharmacokinetics (PK): Maximum Concentration (Cmax) of Lasmiditan</measure>
    <time_frame>Predose up to 120 hour postdose</time_frame>
    <description>PK: Cmax of Lasmiditan</description>
  </primary_outcome>
  <primary_outcome>
    <measure>PK: Area Under the Concentration Versus Time Curve From Time Zero to Infinity (AUC[0-inf]) of Lasmiditan</measure>
    <time_frame>Predose up to 120 hour postdose</time_frame>
    <description>PK: AUC[0-inf] of Lasmiditan</description>
  </primary_outcome>
  <primary_outcome>
    <measure>PK: Area Under the Plasma Concentration Versus Time Curve From Time Zero to the Last Measured Concentration Value (AUC[0-tlast]) of Lasmiditan</measure>
    <time_frame>Predose up to 120 hour postdose</time_frame>
    <description>PK: AUC[0-tlast] of Lasmiditan</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">47</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Lasmiditan (DOSE 1)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants will receive lasmiditan as immediate-release (IR) tablet formulation administered orally.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Lasmiditan (DOSE 2)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive lasmiditan as oral-disintegrating (OD) tablet formulation administered orally without water.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Lasmiditan (DOSE 3)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive lasmiditan as oral-disintegrating (OD) tablet formulation administered orally with water.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lasmiditan</intervention_name>
    <description>Administered orally.</description>
    <arm_group_label>Lasmiditan (DOSE 1)</arm_group_label>
    <arm_group_label>Lasmiditan (DOSE 2)</arm_group_label>
    <arm_group_label>Lasmiditan (DOSE 3)</arm_group_label>
    <other_name>LY573144</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Are overtly healthy as determined by medical evaluation.&#xD;
&#xD;
          -  Body mass index (BMI) of 19 to 35 kilograms per meter squared (kg/mÂ²).&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Have known allergies to lasmiditan, related compounds, or any components of the&#xD;
             formulation of lasmiditan, or a history of significant atopy.&#xD;
&#xD;
          -  Have an abnormal blood pressure and/or pulse rate, as determined by the investigator.&#xD;
&#xD;
          -  Have clinically significant abnormalities on ECG, as determined by investigator.&#xD;
&#xD;
          -  Have a history or presence of cardiovascular, respiratory, renal, gastrointestinal,&#xD;
             endocrine, hematological, or neurological disorders capable of significantly altering&#xD;
             the absorption, metabolism, or elimination of drugs; of constituting a risk when&#xD;
             taking the study interventions; or of interfering with the interpretation of data.&#xD;
&#xD;
          -  Have used or are intending to use over-the-counter or prescription medication,&#xD;
             including dietary supplements, within 14 days prior to dosing and until study&#xD;
             discharge (apart from occasional acetaminophen, hormonal contraception, or&#xD;
             hormone-replacement therapy).&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)</last_name>
    <role>Study Director</role>
    <affiliation>Eli Lilly and Company</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Covance Dallas</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75247</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>May 10, 2021</study_first_submitted>
  <study_first_submitted_qc>May 10, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">May 11, 2021</study_first_posted>
  <last_update_submitted>August 11, 2021</last_update_submitted>
  <last_update_submitted_qc>August 11, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 12, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lasmiditan</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

